deucravacitinib
bms
['poetyk,pso-4', 'deucra', 'psoriasis']
congress #wcd2023singapore | yayoi tada, teikyo university, presents pros in pts with moderate-to-severe plaque psoriasis, gpp, &amp; ep, treated with deucravacitinib in japan from poetyk pso-4 study. n=74. at w16, improvement in dlqi scores were reported with mean change from 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource that provides balanced and up-to-date medical education. #Psoriasis #RheumTwitter